Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line

International Journal of Oncology

Volumn 37, Issue 6, 2010, Pages 1555-1563

  Mriouah, Jihane ^a   Boura, Cedric ^a   Pinel, Sophie ^a   Chretien, Anne Sophie ^a,c   Fifre, Alexandre ^b   Merlin, Jean Louis ^a,c   Faivre, Beatrice ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

Author keywords

AKT; Cetuximab; ERK 1 2; G2M phase; Head and neck squamous cell carcinoma; pEGFR; PTEN

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTINEMATODAL AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; NEOPLASMS, SQUAMOUS CELL; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78649972439     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000809     Document Type: Article

References (39)

1. Jorissen RN, Walker F, Pouliot N, Garett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284: 31-35, 2003.
2. Yarden Y: The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 4: S3-S8, 2001.
3. Mendelsohn J and Baselga J: The EGF receptor family as target for cancer therapy. Oncogene: 19: 6550-6565, 2000.
4. Monnier L, Milano G, Penault-Llorca F, and Merlin JL: Targeting of membrane receptor tyrosine kinases: is there resistance in the HER? Bull Cancer 91: 685-694, 2004.
5. Reuter CWM, Morgan MA and Eckardt A: Targeting EGF-receptor-signaling in squamous cell carcinomas of the head and neck. Br J Cancer 96: 408-416, 2007.
6. Ford AC and Grandis JR: Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25: 67-73, 2003. (Pubitemid 36005333)
7. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708, 2004. (Pubitemid 40065545)
8. Cohen EEW: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2659-2665, 2006. (Pubitemid 46622087)
9. Morgillo F, Bareschino MA, Bianco R, Tortora G and Ciardello F: Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75: 788-799, 2007.
10. Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD, Lee JI and Hong SP: Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 58: 1199-1205, 2005.
11. Yamatodani T, Ekblad L, Kjellen E, Johnsson A, Mineta H and Wennerberg J: EGFR status and persistent activation of Akt and p44/p42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 135: 395-402, 2009.
12. Albanell J, Codony-Servat J, Rojo J, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J and Baselga J: Activated extracellular signal-regulated kinases: association with EGFR/TGFα expression in HNSCC and inhibition by anti-EGFR treatments. Cancer Res 61: 6500-6510, 2001.
13. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lièvre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S and Penault-Llorca F: Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930, 2009.
14. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I and Cascinu S: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009.
15. Balko JM and Black EP: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 9: 145-155, 2009.
16. Janmaat ML, Kruyt FAE, Rodriguez JA and Giaccone G: Response to EGFR inhibitors in NSCLCC: limited antiproiferative effects and absence of apoptosis associated with persistent activity of ERK or AKT kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.
17. She QB, Solit D, Basso A, and Moasser MM: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9: 4340-4346, 2003.
18. Pandolfi PP: Breast Cancer - loss of PTEN predicts resistance to treatment. N Engl J Med 351: 337-2338, 2004.
19. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez Soler R and Mariadason JM: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the EGFR inhibitor cetuximab. Cancer Res 68: 1953-1961, 2008.
20. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F and Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145, 2007. (Pubitemid 47587019)
21. Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P and Merlin JL: PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAFMAPK downstream signaling in KRas wild-type hormone refractory prostate cancer cells. Oncol Rep 21: 731-735, 2009.
22. Liu W, Zhou Y, Reske SN and Shen C: PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res 28: 3613-3620, 2008.
23. Ali IU, Schriml LM and Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932, 1999.
24. Gu J, Tamura M and Yamada K: Tumor suppressor PTEN inhibits integrin- and growth factor-mediated MAP kinase signaling pathways. J Cell Biol 143: 1375-1383, 1998.
25. Sansal I and Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963, 2004.
26. Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, Ki Hong W and Mao L: Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 127: 1441-1445, 2001. (Pubitemid 33150608)
27. Squarize CH, Castilho RM and Santos Pinto D: Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J Oral Pathol Med 7: 379-384, 2002
28. Schimanski CC, Linnemann U and Berger MR: Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59: 5169-5175, 1999.
29. Chergui F, Chrétien AS, Bouali S, Ramacci C, Rouyer M, Bastogne T, Genin P, Leroux A and Merlin JL: Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer. Clin Chem 55: 1327-1336, 2009.
30. Weber A, Langhanki L, Sommerer S, Markwarth A, Wittekind C and Tannapfel A: Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22: 4757-4759, 2003. (Pubitemid 36976451)
31. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN and Papadimitrakopoulou VA: Akt activation correlates with adverse outcome in tongue cancer. Cancer 104: 2430-2436, 2005.
32. Pedrero JMG, Carracedo DG, Munoz Pinto C, Zapatero AH, Rodrigo JP, Nieto CS and Gonzalez MV: Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114: 244-248, 2005.
33. (Ink4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 63: 92-98, 2002.
34. Harari PM and Huang SM: Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49: 427-433, 2001.
35. Maehama T: PTEN: its deregulation and tumorigenesis. Biol Pharm Bull 30: 1624-1627, 2007.
36. Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Ho Park B, Martin SS, Weber DJ and Bachman KE: Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res 69: 8275-8283, 2009.
37. Hayashi H, Tsuchiya Y, Nakayama K, Satoh T and Nishida E: Down-regulation of the PI3-kinase/AKT pathway by ERK MAP Kinase in growth factor signaling. Genes Cells 13: 941-947, 2008.
38. Weng LP, Brown JL and Eng C: PTEN induces apoptosis and cell cycle arrest through PI3K/AKT-dependent and independent pathways. Hum Mol Genet 10: 237-242, 2001.
39. Chung JH, Ostrowski MC, Roomigh T, Minaguchi T, Waite KA and Eng C: The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet 17: 2553-2559, 2006. (Pubitemid 44288685)